Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of EG-Mirotin in diabetic macular edema
2014-001351-23Phase 2Terminated
- Sponsor
- EyeGene, Inc.
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) and diabetic retinopathy (DR) comparing EG-Mirotin with Placebo (2 arms). Started May 2017; status: terminated.
02
Drugs
EG-Mirotin
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2014-001351-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001351-23.